The Latest Breaking News from SciSparc

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures

SciSparc Ltd. (NASDAQ:SPRC) traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures Inc. (TSXV:MIZA), a publicly traded firm on Canada's TSX Venture Exchange

Benzinga · Oct 15, 2025

SciSparc And AutoMax Call Off Merger

SciSparc Ltd. (NASDAQ:SPRC) said Monday it has entered a framework agreement with AutoMax Motors Ltd. to mutually terminate their planned merger, officially ending a deal that would have expanded the company into Israel’s automotive market.

Benzinga · Oct 6, 2025

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Ltd. (NASDAQ: SPRC) stock is surging on Thursday, with a session volume of 58.21 million compared to the average volume of 2.49 million as per data from Benzinga Pro.

Benzinga · Sep 25, 2025

SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon

SciSparc Ltd. (NASDAQ: SPRC) signed a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution, an Amazon.com (NASDAQ:

Benzinga · Sep 14, 2022

Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.

Benzinga · Aug 24, 2022

SPRC: Clinical-stage pharma company using cannabinoids to address serious health issues.

By Brad Sorensen, CFA NASDAQ:SPRC

Benzinga · Jul 21, 2022

SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S.

Benzinga · Jul 8, 2022

SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upc

Benzinga · Jun 29, 2022

EXCLUSIVE: SciSparc' Board To Review Potential Strategic Transactions

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focused on the endocannabinoid system, plans to review potential strategic transactions.

Benzinga · Jun 9, 2022

Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies

The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.

Benzinga · Jun 8, 2022